Healthcare / BiotechnologyNasdaqGM
$6.92
-0.28 (-3.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-81.1M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$715M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-77.6%
↓Gross Margin
N/A
•Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-106.2M · FCF $-85.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-106.2M | $-106.2M | $-86.9M | $-76.4M | $-58.8M | $-35.3M | $-22.2M |
| EBITDA | $-111.7M | $-111.7M | $-94.9M | $-83.7M | $-59.1M | — | — |
| EPS | -1.76 | -1.76 | -1.75 | -1.93 | -1.96 | -8.95 | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.13 | 0.13 | 0.12 | 0.09 | 0.11 | — | — |
| Current Ratio | 7.09 | 7.09 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-85.2M | $-85.2M | $-81.1M | $-64.6M | $-55.7M | $-34.5M | $-25.1M |
| Returns | |||||||
| ROE | -77.6% | -77.6% | -57.2% | -33.8% | -30.0% | -23.1% | 20.4% |
| Valuation | |||||||
| P/B | 3.05 | 3.05 | 2.76 | 1.55 | 1.61 | — | — |
| Growth & Yield | |||||||
| EPS Growth | -0.6% | -0.6% | 9.3% | 1.5% | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.75 → -1.76
Residual
+12.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.